<DOC>
	<DOC>NCT02460679</DOC>
	<brief_summary>Open label study with EPI-589 and ALS subjects</brief_summary>
	<brief_title>Safety and Biomarker Study of EPI-589 in Subjects With ALS</brief_title>
	<detailed_description>Open label with 30-day run in phase to establish baseline parameters and a 90-day withdrawal phase to determine duration of treatment response.</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Motor Neuron Disease</mesh_term>
	<mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
	<criteria>Dx. of ALS by E1 Escorial Criteria FVC &gt;= 70% years of age Weakness onset within 3 years Agreement to use contraception when age appropriate Willingness and ability to comply with study procedures Stable regimen of dietary supplements and /or riluzole for at least 30 days prior to study Absention from use of other investigative or nonapproved drugs Subject must be able to swallow size 0 tablets Allergy to EPI589 Use of ventilation Participation in other intervention studies Inability to undergo MRI or MRS Dx with any other neurologic disease Malignancy within the past 2 years Hx. of stroke Hx. of brain injury Hepatic insufficiency (LFTs &gt; 3 xs ULN) Renal insufficiency requiring dialysis End stage cardiac failure Participation in a trial of a device, drug or other tx. for ALS within 3 months</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>